Icatibant Synchrony Pharma (Icatibant)

Icatibant works as a selective competitive antagonist of the bradykinin B2 receptor. By occupying this receptor on vascular endothelial cells, it prevents bradykinin from triggering vasodilation and increased vascular permeability, which are the primary mechanisms behind the swelling seen in hereditary angioedema.

The dose of icatibant is determined by the prescribing healthcare professional based on the patient’s clinical condition and regulatory guidelines. The medication is administered as a subcutaneous injection, and the prescriber will specify the exact amount and frequency required for each acute HAE episode.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will assess individual circumstances before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other HAE therapies such as C1‑inhibitor concentrates replace the deficient protein, and monoclonal antibodies target different pathways. Icatibant provides rapid symptom relief through direct receptor blockade, making it useful for patients who prefer subcutaneous self‑administration or when protein‑based products are unavailable.

Icatibant solution for injection should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period, then return to refrigeration as soon as possible.

Icatibant is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after appropriate instruction, by the patient or caregiver. The site should be rotated for each dose, and aseptic technique must be followed to minimize infection risk.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, marked hypotension, and paradoxical worsening of angioedema despite treatment. Patients should be monitored closely after injection, and any signs of severe allergic reaction or sudden blood pressure drop require immediate medical attention.

Icatibant should be avoided in individuals with known hypersensitivity to icatibant or any of its excipients. Patients taking ACE inhibitors or ARBs should use it only under close medical supervision due to an increased risk of angioedema. It is also contraindicated in patients with severe uncontrolled hypotension.